R. Roman

发表

Clinicopathological and molecular characterization of colorectal micropapillary carcinoma

X. Puig, A. Vidal, N. Rodón, 2011, Modern Pathology.

RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients

A. Giménez-Capitán, M. Molina-Vila, S. Viteri, 2020, Diagnostics.

Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostate-specific antigen

X. Puig, I. Trias, J. M. Banús, 2014 .

Genetic and Immunophenotype Analyses of TP53 in Bladder Cancer: TP53 Alterations Are Associated with Tumor Progression

C. Cordon-Cardo, E. Condom, N. Hannaoui, 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas

C. Cordon-Cardo, X. Puig, A. Vidal, 2003, Applied immunohistochemistry & molecular morphology : AIMM.

ERG expression and prostatic adenocarcinoma

X. Puig, I. Trias, J. M. Banús, 2013, Virchows Archiv.

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer

R. Rosell, N. Viñolas, A. Prat, 2020, Molecular oncology.

A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer.

C. Cordon-Cardo, X. Puig, A. Vidal, 2005, The Journal of molecular diagnostics : JMD.

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

J. Wolchok, J. Allison, M. Callahan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

J. Wolchok, J. Allison, C. Ariyan, 2010, Cancer immunity.

Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection

J. Wolchok, G. Schwartz, A. Houghton, 2010, Clinical Cancer Research.

Prospective validation of the microsatellite instability prediction models: RERtest6 and RERtest8

X. Puig, N. Rodón, M. Verdú, 2015 .

Fluorescent in situ hybridization as a predictor of relapse in urothelial carcinoma.

X. Puig, I. Trias, J. M. Banús, 2013, Actas urologicas espanolas.

CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.

J. Wolchok, A. Yang, Jianda Yuan, 2010 .

KIT as a therapeutic target in metastatic melanoma.

C. Antonescu, J. Wolchok, G. Schwartz, 2011, JAMA.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

J. Wolchok, J. Allison, N. Segal, 2008, Proceedings of the National Academy of Sciences.

Microsatellite instability of the colorectal carcinoma can be predicted in the conventional pathologic examination. A prospective multicentric study and the statistical analysis of 615 cases consolidate our previously proposed logistic regression model

X. Puig, I. Trias, A. Vidal, 2010, Virchows Archiv.

A Novel Logistic Model Based on Clinicopathological Features Predicts Microsatellite Instability in Colorectal Carcinomas

C. Cordon-Cardo, X. Puig, A. Vidal, 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Immunologic correlates of the abscopal effect in a patient with melanoma.

Jedd D. Wolchok, Yoshiya Yamada, Ramon Chua, 2012, The New England journal of medicine.

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

R. Rosell, A. Cardona, J. Castellví, 2019, Nature Communications.

Immunotherapy for advanced melanoma.

R. Roman, 2011, Clinical journal of oncology nursing.

Cross-reactivity of EGFR L858R mutation-specific antibody in HER2 positive gastric adenocarcinomas

X. Puig, I. Trias, N. Rodón, 2015 .

Reference standards for gene fusion molecular assays on cytological samples: an international validation study

G. Fontanini, B. Weynand, R. Rosell, 2021, Journal of Clinical Pathology.

Cross-reactivity of EGFR Mutation-specific Immunohistochemistry Assay in HER2-positive Tumors

X. Puig, I. Trias, N. Rodón, 2015, Applied immunohistochemistry & molecular morphology : AIMM.

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

R. Rosell, A. Cardona, J. Castellví, 2019, Nature Communications.

EGFR mutations in lung cancer

X. Puig, I. Trias, N. Rodón, 2016 .

The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.

J. Wolchok, M. Callahan, J. Wigginton, 2012 .

Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience.

J. Wolchok, G. Schwartz, C. Barker, 2012 .

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

H. Ditzel, C. Tornador, G. Fabbri, 2023, Molecular Cancer.

Diagnostic and predictive value of urine PCA3 gene expression for the clinical management of patients with altered prostatic specific antigen.

X. Puig, I. Trias, J. M. Banús, 2014, Actas urologicas espanolas.

Phase II trial of neoadjuvant temozolomide in advanced melanoma

N. Socci, A. Viale, J. Wolchok, 2008 .